|Bid||7.86 x 2900|
|Ask||8.76 x 800|
|Day's Range||7.85 - 8.59|
|52 Week Range||7.85 - 33.55|
|Beta (5Y Monthly)||1.61|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 21, 2022 - Feb 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.91|
Subscribe to Yahoo Finance Plus to view Fair Value for BLUELearn more
CAMBRIDGE, Mass., January 18, 2022--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for its lentiviral vector gene therapies – betibeglogene autotemcel (beti-cel) for β-thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD). The revised PDUFA goal dates for beti-cel and eli-cel are August 19, 2022 and September 16, 2022, respectively.
Shares of gene therapy company Bluebird Bio (NASDAQ: BLUE) fell by 10.7% through the first four full days of trading this week, according to data provided by S&P Global Market Intelligence. With two potential regulatory approvals and commercial launches coming down the pike later this year, Bluebird's most recent cash, cash equivalents, and marketable securities balance of approximately $442 million probably won't be sufficient to meet its short-term financial needs. On a positive note, Bluebird said it plans on exploring the sale for the priority review vouchers expected to be issued with the U.S. approvals of its gene therapies known as beti-cel and eli-cel, respectively.
Following the spinout of its cancer business, bluebird bio Inc. is all in on gene therapy, with plans to launch three new drugs by the end of 2023.